CoV-2 Spike E-Mosaic
CoV 2019 Spike E-Mosaic Protein is >90% pure as determined SDS-PAGE.
Description
The E.Coli derived recombinant protein contains the Coronavirus 2019 spike Envelope Mosaic immunodominant regions having a Mwq of 40.5 kDa, fused to 6xHis tag at C-terminal.
Product Specs
In December 2019, a novel coronavirus, designated 2019-nCoV, emerged in Wuhan, China, causing viral pneumonia in humans. The virus was initially linked to a seafood market.
Genetic analysis revealed that 2019-nCoV shares 87% identity with the SARS-CoV-2 virus found in bats in eastern China in 2018. Despite some differences in their amino acid sequences, the receptor-binding domain (RBD) of 2019-nCoV is structurally similar to that of the 2018 bat virus, suggesting that it may also target the human ACE2 receptor (angiotensin-converting enzyme 2).
While bats are considered the likely reservoir of 2019-nCoV, researchers believe an intermediate animal host, potentially from the seafood market, played a role in its transmission to humans. Studies indicate that the virus's spike glycoprotein is a recombinant between a bat coronavirus and an unidentified coronavirus.
This recombinant protein is derived from E. coli and contains immunodominant regions of the Coronavirus 2019 spike protein's Envelope Mosaic region. It has a molecular weight of 40.5 kDa and is fused with a 6xHis tag at the C-terminus.
The CoV 2019 Spike E-Mosaic Protein is provided at a concentration of 1mg/ml in a solution of 1x PBS (phosphate-buffered saline).
The CoV 2019 Spike E-Mosaic Protein is shipped with ice packs to maintain its stability. Upon receipt, it should be stored at -20°C.
SDS-PAGE analysis indicates that the purity of the CoV 2019 Spike E-Mosaic Protein is greater than 90%.
S-part (20-210 a.a.)
RTQLPPAYTN SFTRGVYYPD KVFRSSVLHS TQDLFLPFFS NVTWFHAIHV SGTNGTKRFD NPVLPFNDGV YFASTEKSNI IRGWIFGTTL DSKTQSLLIV NNATNVVIKV CEFQFCNDPF LGVYYHKNNK SWMESEFRVY SSANNCTFEY VSQPFLMDLE GKQGNFKNLR EFVFKNIDGY FKIYSKHTPI
E-part (51-75 a.a.)
AYCCNIVNVS LVKPSFYVYS RVKNLNSSRV PDLLV
M part (100-222 a.a.)
RLFARTRSMW SFNPETNILL NVPLHGTILT RPLLESELVI GAVILRGHLR IAGHHLGRCD
IKDLPKEITV ATSRTLSYYK LGASQRVAGD SGFAAYSRYR IGNYKLNTDH SSSSDNIALL VQ
Product Science Overview
The E-Mosaic Recombinant is based on the spike protein of SARS-CoV-2, which is the primary target for neutralizing antibodies. The spike protein facilitates the virus’s entry into host cells by binding to the ACE2 receptor. The recombinant version, known as the mosaic-type trimeric receptor-binding domain (mos-tri-RBD), includes mutations from several variants of concern, such as Omicron, Beta, and Delta .
Preclinical studies have shown that the mos-tri-RBD induces significantly higher neutralizing antibody titers compared to vaccines based on the ancestral strain of SARS-CoV-2. Tests in animal models, such as rats, demonstrated that the mos-tri-RBD elicited strong immune responses against Omicron and other immune-evasive variants .
The development of the Coronavirus 2019 Spike E-Mosaic Recombinant represents a significant advancement in the fight against COVID-19. By incorporating mutations from multiple variants, this recombinant protein has the potential to provide broader protection and help control the spread of emerging variants .
Ongoing research and clinical trials are essential to further evaluate the safety and efficacy of the E-Mosaic Recombinant in humans. If successful, this approach could pave the way for the development of next-generation vaccines that offer robust protection against a wide range of SARS-CoV-2 variants .
